-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, O/Wn9KO/MxEjzUrpaGCEb1sqnxYoRf8oUcI+zXK7OcpF67js1mKugQXfIsIlxrpv YBDOF5I7odrxds2cqy3uWA== 0000950123-09-009123.txt : 20090713 0000950123-09-009123.hdr.sgml : 20090713 20090519160201 ACCESSION NUMBER: 0000950123-09-009123 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS INC CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 6 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 6 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 CORRESP 1 filename1.htm CORRESP
AMICUS THERAPEUTICS, INC.
6 Cedar Brook Drive
Cranbury, New Jersey 08512
May 19, 2009
Via EDGAR and Facsimile
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Jeffrey R. Riedler
     
Re:
  Amicus Therapeutics, Inc,
Registration Statement on Form S-3, as amended
File No. 333-158405
Ladies and Gentlemen:
     Pursuant to Rule 461 of the Securities Act of 1933, as amended, and Rule 12(b)-6 of the Securities Exchange Act of 1934, as amended, Amicus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that the effectiveness of the Company’s above-referenced Registration Statement on Form S-3, as amended, be accelerated to 5 p.m. Eastern Time on Thursday, May 21, 2009, or as soon as practicable thereafter, unless you are orally or in writing notified to the contrary by the Company prior to such date and time.
     The Company hereby acknowledges that:
 
  • should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
  • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
  • the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
     Should you have any questions regarding this request, please do not hesitate to contact Julio E. Vega (617-951-8901) or Meerie M. Joung (617-951-8840) of Bingham McCutchen LLP.
     Sincerely,
AMICUS THERAPEUTICS, INC.
 
         
     
  /s/ John F. Crowley    
  John F. Crowley
Chief Executive Officer and President;		  
     
cc:
  Julio E. Vega, Esq., Bingham McCutchen LLP
 Meerie M. Joung, Esq., Bingham McCutchen LLP
 Geoffrey Gilmore, Esq., Amicus Therapeutics, Inc.
 Peter Macaluso, Esq., Amicus Therapeutics, Inc.

-----END PRIVACY-ENHANCED MESSAGE-----